Copyright Reports & Markets. All rights reserved.

Global Drugs for PrEP Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Drugs for PrEP Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Oral Drugs
    • 1.3.3 Injections
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Drugs for PrEP Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Pharmacy
    • 1.4.4 Other
  • 1.5 Global Drugs for PrEP Market Size & Forecast
    • 1.5.1 Global Drugs for PrEP Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Drugs for PrEP Sales Quantity (2021-2032)
    • 1.5.3 Global Drugs for PrEP Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Gilead Sciences
    • 2.1.1 Gilead Sciences Details
    • 2.1.2 Gilead Sciences Major Business
    • 2.1.3 Gilead Sciences Drugs for PrEP Product and Services
    • 2.1.4 Gilead Sciences Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Gilead Sciences Recent Developments/Updates
  • 2.2 ViiV Healthcare
    • 2.2.1 ViiV Healthcare Details
    • 2.2.2 ViiV Healthcare Major Business
    • 2.2.3 ViiV Healthcare Drugs for PrEP Product and Services
    • 2.2.4 ViiV Healthcare Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 ViiV Healthcare Recent Developments/Updates
  • 2.3 Teva
    • 2.3.1 Teva Details
    • 2.3.2 Teva Major Business
    • 2.3.3 Teva Drugs for PrEP Product and Services
    • 2.3.4 Teva Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Teva Recent Developments/Updates
  • 2.4 Amneal Pharmaceuticals
    • 2.4.1 Amneal Pharmaceuticals Details
    • 2.4.2 Amneal Pharmaceuticals Major Business
    • 2.4.3 Amneal Pharmaceuticals Drugs for PrEP Product and Services
    • 2.4.4 Amneal Pharmaceuticals Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Amneal Pharmaceuticals Recent Developments/Updates
  • 2.5 Aurobindo Pharma
    • 2.5.1 Aurobindo Pharma Details
    • 2.5.2 Aurobindo Pharma Major Business
    • 2.5.3 Aurobindo Pharma Drugs for PrEP Product and Services
    • 2.5.4 Aurobindo Pharma Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Aurobindo Pharma Recent Developments/Updates
  • 2.6 Mylan
    • 2.6.1 Mylan Details
    • 2.6.2 Mylan Major Business
    • 2.6.3 Mylan Drugs for PrEP Product and Services
    • 2.6.4 Mylan Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Mylan Recent Developments/Updates
  • 2.7 Zydus
    • 2.7.1 Zydus Details
    • 2.7.2 Zydus Major Business
    • 2.7.3 Zydus Drugs for PrEP Product and Services
    • 2.7.4 Zydus Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Zydus Recent Developments/Updates
  • 2.8 Qilu Pharmaceutical
    • 2.8.1 Qilu Pharmaceutical Details
    • 2.8.2 Qilu Pharmaceutical Major Business
    • 2.8.3 Qilu Pharmaceutical Drugs for PrEP Product and Services
    • 2.8.4 Qilu Pharmaceutical Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.9 Anhui Baker Biopharmaceutical
    • 2.9.1 Anhui Baker Biopharmaceutical Details
    • 2.9.2 Anhui Baker Biopharmaceutical Major Business
    • 2.9.3 Anhui Baker Biopharmaceutical Drugs for PrEP Product and Services
    • 2.9.4 Anhui Baker Biopharmaceutical Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Anhui Baker Biopharmaceutical Recent Developments/Updates
  • 2.10 Chengdu Brilliant Pharmaceutical
    • 2.10.1 Chengdu Brilliant Pharmaceutical Details
    • 2.10.2 Chengdu Brilliant Pharmaceutical Major Business
    • 2.10.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product and Services
    • 2.10.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Chengdu Brilliant Pharmaceutical Recent Developments/Updates
  • 2.11 North China Pharmaceutical
    • 2.11.1 North China Pharmaceutical Details
    • 2.11.2 North China Pharmaceutical Major Business
    • 2.11.3 North China Pharmaceutical Drugs for PrEP Product and Services
    • 2.11.4 North China Pharmaceutical Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 North China Pharmaceutical Recent Developments/Updates
  • 2.12 Chia Tai Tianqing Pharmaceutical
    • 2.12.1 Chia Tai Tianqing Pharmaceutical Details
    • 2.12.2 Chia Tai Tianqing Pharmaceutical Major Business
    • 2.12.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product and Services
    • 2.12.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Drugs for PrEP by Manufacturer

  • 3.1 Global Drugs for PrEP Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Drugs for PrEP Revenue by Manufacturer (2021-2026)
  • 3.3 Global Drugs for PrEP Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Drugs for PrEP by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Drugs for PrEP Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Drugs for PrEP Manufacturer Market Share in 2025
  • 3.5 Drugs for PrEP Market: Overall Company Footprint Analysis
    • 3.5.1 Drugs for PrEP Market: Region Footprint
    • 3.5.2 Drugs for PrEP Market: Company Product Type Footprint
    • 3.5.3 Drugs for PrEP Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Drugs for PrEP Market Size by Region
    • 4.1.1 Global Drugs for PrEP Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Drugs for PrEP Consumption Value by Region (2021-2032)
    • 4.1.3 Global Drugs for PrEP Average Price by Region (2021-2032)
  • 4.2 North America Drugs for PrEP Consumption Value (2021-2032)
  • 4.3 Europe Drugs for PrEP Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Drugs for PrEP Consumption Value (2021-2032)
  • 4.5 South America Drugs for PrEP Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Drugs for PrEP Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Drugs for PrEP Sales Quantity by Type (2021-2032)
  • 5.2 Global Drugs for PrEP Consumption Value by Type (2021-2032)
  • 5.3 Global Drugs for PrEP Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Drugs for PrEP Sales Quantity by Application (2021-2032)
  • 6.2 Global Drugs for PrEP Consumption Value by Application (2021-2032)
  • 6.3 Global Drugs for PrEP Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Drugs for PrEP Sales Quantity by Type (2021-2032)
  • 7.2 North America Drugs for PrEP Sales Quantity by Application (2021-2032)
  • 7.3 North America Drugs for PrEP Market Size by Country
    • 7.3.1 North America Drugs for PrEP Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Drugs for PrEP Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Drugs for PrEP Sales Quantity by Type (2021-2032)
  • 8.2 Europe Drugs for PrEP Sales Quantity by Application (2021-2032)
  • 8.3 Europe Drugs for PrEP Market Size by Country
    • 8.3.1 Europe Drugs for PrEP Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Drugs for PrEP Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Drugs for PrEP Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Drugs for PrEP Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Drugs for PrEP Market Size by Region
    • 9.3.1 Asia-Pacific Drugs for PrEP Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Drugs for PrEP Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Drugs for PrEP Sales Quantity by Type (2021-2032)
  • 10.2 South America Drugs for PrEP Sales Quantity by Application (2021-2032)
  • 10.3 South America Drugs for PrEP Market Size by Country
    • 10.3.1 South America Drugs for PrEP Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Drugs for PrEP Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Drugs for PrEP Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Drugs for PrEP Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Drugs for PrEP Market Size by Country
    • 11.3.1 Middle East & Africa Drugs for PrEP Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Drugs for PrEP Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Drugs for PrEP Market Drivers
  • 12.2 Drugs for PrEP Market Restraints
  • 12.3 Drugs for PrEP Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Drugs for PrEP and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Drugs for PrEP
  • 13.3 Drugs for PrEP Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Drugs for PrEP Typical Distributors
  • 14.3 Drugs for PrEP Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Drugs for PrEP market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Drugs for Pre-Exposure Prophylaxis (PrEP) are antiretroviral medications used to prevent HIV infection in individuals at high risk of exposure. These drugs work by blocking the replication of HIV in the body if exposure occurs, significantly reducing the risk of infection. Taken daily, PrEP can lower HIV transmission risk by up to 99%. PrEP is recommended for individuals at high risk, such as men who have sex with men (MSM), people with HIV-positive partners, or those who engage in high-risk sexual activities or injectable drug use. In addition to oral medications, long-acting injectable forms like cabotegravir are being developed and used to enhance adherence and accessibility.
    This report is a detailed and comprehensive analysis for global Drugs for PrEP market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Drugs for PrEP market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for PrEP market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for PrEP market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for PrEP market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Drugs for PrEP
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Drugs for PrEP market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Drugs for PrEP market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Oral Drugs
    Injections
    Market segment by Application
    Hospital and Clinic
    Pharmacy
    Other
    Major players covered
    Gilead Sciences
    ViiV Healthcare
    Teva
    Amneal Pharmaceuticals
    Aurobindo Pharma
    Mylan
    Zydus
    Qilu Pharmaceutical
    Anhui Baker Biopharmaceutical
    Chengdu Brilliant Pharmaceutical
    North China Pharmaceutical
    Chia Tai Tianqing Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Drugs for PrEP product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Drugs for PrEP, with price, sales quantity, revenue, and global market share of Drugs for PrEP from 2021 to 2026.
    Chapter 3, the Drugs for PrEP competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Drugs for PrEP breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for PrEP market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for PrEP.
    Chapter 14 and 15, to describe Drugs for PrEP sales channel, distributors, customers, research findings and conclusion.

    Buy now